Plymouth Pharmaceuticals™, Inc. and its division, Loma Lux Laboratories, is dedicated to promoting worldwide health and wholeness. Our focus is the discovery, research, and development of natural, low dose, low side effect treatments that bring freedom from chronic diseases through correction of basic underlying disease mechanisms.
Responsible manufacturing practices, integrity of our advertisements, and prompt, efficient service are central to our corporate philosophy. Furthermore, it is our mission to make these treatments widely and easily available to those who need them.
*Note: These files are in PDF format. If you do not have a PDF reader installed, you may download Adobe Reader for free by clicking here.
Plymouth Pharmaceuticals™ was incorporated in 1991 under the direction of Steven A. Smith, M.D., FACP, a dermatologist; his original intent was to create a new treatment for people who suffer with psoriasis. Dr. Smith originally initiated a traditional, allopathic IND (Investigational New Drug) application process with FDA (Food & Drug Administration) to get his ORAL psoriasis medication approved for use in the United States. The term “allopathic (conventional) medicine” was coined in 1842 by Dr. Samuel Hahnemann, the father of homeopathy, and has been used ever since to distinguish “homeopathic” medicines from traditional medicines (those having gained FDA approval through an IND application).
Two years after filing the IND application, Dr. Smith discovered that the main components of his psoriasis medication were already “grandfathered in” under the HPUS (Homeopathic Pharmacopoeia of the United States). The USP (United States Pharmacopoeia) is used for all allopathic medicines and dietary supplements worldwide. All ingredients, including those Dr. Smith had discovered, listed in the HPUS were already accepted by FDA as safe; therefore, Loma Lux® Psoriasis could be marketed by filing only a handful of forms with FDA. Loma Lux’s only cost would be to ramp up inventory and market the product. This allowed the company to leapfrog many of its competitors without the need for a typical IND process, which is can take up to 15 years and $300 million just to get a new drug approved by FDA.
The launch of a homeopathic OTC (over the counter) psoriasis product as well as acne and eczema came in 1996; these products were and still are sold under the Loma Lux® brand. All of the Loma Lux® products are available through various online distributors, among them www.amazon.com and www.drugstore.com.
In 1999, the company launched its first homeopathic “Rx only” product, Psorizide® Ultra, to treat psoriasis, eczema, and seborrhea. Psorizide® Ultra was then reformulated for the treatment of psoriasis specifically and became Psorizide® Forte (Rx) in 2001; at that time Psorizide® Ultra’s indication became solely the treatment of eczema and seborrhea. Eczemol® (Rx) for the treatment of moderate to severe eczema, and Acunol™ (Rx), for the treatment of mild to moderate acne were launched in 2006. All prescription products are sold under the Plymouth Pharmaceuticals™ brand.
Site designed by Capital Creatives.